Technology ID
TAB-4905
Bolstering HIV Vaccine Development: MVA Vector Expressing Functional B13R Gene
E-Numbers
E-090-2017-0
Lead Inventor
Wyatt, Linda
Lead IC
NIAID
Co-Inventors
Moss, Bernard
ICs
NIAID
Applications
Vaccines
Therapeutic Areas
Infectious Disease
Development Stages
Clinical Phase I
Research Products
Plasmids/Vectors
The technology involves the use of Modified Vaccinia Ankara (MVA) as a vaccine vector for HIV. MVA is a safe and immunogenic poxvirus vector that can accommodate large gene insertions. In this case, researchers have modified MVA to express a functional B13R gene, which helps delay apoptosis (cell death) of infected cells. This modification aims to enhance the immune response against HIV. The technology has shown promise in pre-clinical studies, demonstrating its potential as a candidate for an HIV vaccine.
Commercial Applications
The application of Modified Vaccinia Ankara (MVA) as a vaccine vector for HIV has broad implications beyond HIV prevention. MVA's safety profile, immunogenicity, and ability to accommodate large gene insertions make it a versatile platform for developing vaccines against various infectious diseases and cancers. Its potential applications include the development of vaccines for other viral infections, such as influenza, Ebola, and Zika virus, as well as for certain types of cancer. Additionally, MVA-based vaccines could be used in combination with existing therapies to enhance their efficacy or as part of a preventive strategy in outbreak situations.
Competitive Advantages
The use of Modified Vaccinia Ankara (MVA) as a vaccine vector for HIV offers a compelling advantage due to its safety, immunogenicity, and capacity for large gene insertions. By expressing a functional B13R gene, MVA enhances the immune response against HIV by delaying cell death, potentially leading to a more effective vaccine. These characteristics position MVA as a strong candidate for developing a preventative HIV vaccine, addressing a critical need in combating the spread of the virus.
Licensing Contact: